Caris Life Sciences

Caris Life Sciences Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Join Caris at the USCAP Annual Meeting in San Antonio, Texas. Visit our team at booth 512 to learn how our comprehensive...
03/17/2026

Join Caris at the USCAP Annual Meeting in San Antonio, Texas. Visit our team at booth 512 to learn how our comprehensive molecular profiling services are helping advance precision medicine and supporting pathologists with deeper insights for clinical decision making.
Learn more and schedule a meeting with our team during the meeting: https://bit.ly/4uztffB

Caris Life Sciences announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI In...
03/16/2026

Caris Life Sciences announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insights™. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy.

“The ability to anticipate which patients are likely to develop early platinum resistance has the potential to significantly improve how we approach ovarian cancer care,” said David Spetzler, MS, PhD, MBA, Caris President.

Learn more: https://ow.ly/k4km50YtNtz

Join pathology leaders and industry collaborators for a Caris Research Collaborators Networking Reception on Monday, Mar...
03/15/2026

Join pathology leaders and industry collaborators for a Caris Research Collaborators Networking Reception on Monday, March 23, 2026. The evening includes networking and a short panel discussion on real world, high impact pathology research conducted with Caris Precision Oncology Alliance institutions and biopharma partners.

Learn more and register: https://www.carislifesciences.com/poa-uscap-2026/

Caris Life Sciences and collaborators from leading cancer centers will collectively present five studies at the 2026 Uni...
03/11/2026

Caris Life Sciences and collaborators from leading cancer centers will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting in San Antonio, Texas, to be held March 21–26, 2026.

“USCAP offers a great opportunity for pathologists to showcase the latest advances and publications in our industry. We’re presenting across multiple topics, incorporating real world outcomes and uncovering insights that bring us closer to truly personalized treatment pathways,” said Matthew Oberley, MD, PhD, SVP, Chief Clinical Officer and Pathologist-in-Chief at Caris.

Learn more: https://ow.ly/nWk150Ys7eQ

Today Caris Life Sciences announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cance...
03/09/2026

Today Caris Life Sciences announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cancer included in the Caris Molecular Tumor Board Report, available upon request with no additional tissue sampling required when ordering MI Cancer Seek®.

Caris advances precision oncology by using AI to analyze data from comprehensive real-world datasets, including its CodeAI™ platform, comprised of over 550,000 patients. By integrating sequencing and clinical data, Caris develops next-generation multimodal models that generate deeper biological insights, accelerate biomarker discovery, and support more personalized cancer treatment decisions.

“By harnessing the power of WES and WTS, this Caris AI Insights signature identifies complex molecular patterns that may predict differential benefit between standard first-line regimens. This is exactly the type of advancement to improve patient care that our comprehensive platform was built to deliver,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences.

Learn more: https://ow.ly/jwHI50YqzqV

Help inspire others through your experience!Sharing your story of survival and experience with Caris molecular testing c...
03/06/2026

Help inspire others through your experience!

Sharing your story of survival and experience with Caris molecular testing can offer invaluable support to others. Let your journey be a source of strength and encouragement. Share your story with us: https://ow.ly/bRJu50WxyAK

In recognition of Colorectal Cancer Awareness Month, we highlight the impact of precision medicine in guiding more targe...
03/04/2026

In recognition of Colorectal Cancer Awareness Month, we highlight the impact of precision medicine in guiding more targeted colorectal cancer treatment.

MI Cancer Seek identifies wild‑type KRAS and NRAS, and BRAF V600E mutations to guide personalized therapy in colorectal cancer. This FDA‑approved companion diagnostic supports anti‑EGFR and BRAF‑targeted combos. Discover MI Cancer Seek’s value in colorectal cancer: https://bit.ly/4lyGNTR

03/02/2026

A recent study from the American Cancer Society shows colorectal cancer is now the leading cause of cancer-related deaths in people under the age of 50 in the United States. During , it’s especially important to highlight advancements that can help change this trajectory.

Caris helps physicians make the most informed treatment decisions for patients with metastatic colorectal cancer by using innovative solutions like Caris FOLFIRSTai, an AI-driven molecular predictor of chemotherapy efficacy. Learn more: https://ow.ly/F0Lj50Yo7gW

Caris Life Sciences completed the interim readout of Achieve 1, the study supporting the upcoming launch of Caris Detect...
02/26/2026

Caris Life Sciences completed the interim readout of Achieve 1, the study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test.

This interim readout of Achieve 1 represents a major milestone in Caris’ goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights.

“This additional data has allowed us to achieve greater performance metrics than others and shows that methodologies focused on limited biological information are not sufficient to encompass the diversity of molecular aberrations driving cancer, especially in early-stage disease,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences


Learn more: https://ow.ly/e0Ag50YmKrA

Caris Life Sciences reported financial results 2025 Q4 and full year, which included full year revenue growth of 97% dri...
02/26/2026

Caris Life Sciences reported financial results 2025 Q4 and full year, which included full year revenue growth of 97% driven by strong performance in molecular profiling services.

The company expects full-year 2026 revenue to be in the range of $1.0 billion to $1.02 billion

Learn more: https://ow.ly/Ign750YmEQP

Every cancer is different, so is every path to treatment. When Balwinder’s family turned to Caris, biomarker testing rev...
02/25/2026

Every cancer is different, so is every path to treatment. When Balwinder’s family turned to Caris, biomarker testing revealed information that helped her care team make the right decisions.

Learn how testing can support more informed cancer care: https://bit.ly/44CJSL0

Caris Life Sciences announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. Caris re...
02/24/2026

Caris Life Sciences announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. Caris recently added the breast cancer signature for capecitabine to the Caris AI Insights section of the report.

“Caris AI Insights help researchers and clinicians provide a valuable molecular blueprint of a patient’s tumor biology and is another way Caris’ testing goes above and beyond for patients, clinicians and researchers,” said Caris President David Spetzler, MS, PhD, MBA.

Learn more: https://ow.ly/W4lf50YkN20

Address

-
Irving, TX
75039

Opening Hours

Monday 7am - 7pm
Tuesday 7am - 7pm
Wednesday 7am - 7pm
Thursday 7am - 7pm
Friday 7am - 7pm

Telephone

+18889798669

Website

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

#WeAreCarisLS

We believe in more treatment options. Because more treatment options, can mean more time with the ones you love the most.

We’re dedicated to fulfilling the promise of precision medicine and changing the face of cancer care by providing the personalized and precise information needed to guide individualized treatment options. Learn more about our suite of market-leading molecular profiling offerings that assesses DNA, RNA and proteins to reveal the highest quality molecular blueprint so you can determine treatment options with confidence: www.carismolecularintelligence.com.